Marie McIlroy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie McIlroy has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Arnold D. Hill
34 shared publications- Leonie S. Young
Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland
24 shared publications - Damir Varešlija
Royal College of Surgeons in Ireland
22 shared publications Fiona T. Bane
22 shared publicationsLaura Creevey
22 shared publicationsLeonie S. Young
21 shared publications
Latest Publications
- Open Access
Integrating Lifestyle, Mechanistic Therapeutics, and Computational Approaches in Cancer: Highlights from the Irish Association for Cancer Research Annual Conference 2025
The Irish Association for Cancer Research (IACR) Annual Conference 2025, held in Belfast, showcased cutting-edge developments across the cancer research landscape. This report summarizes key presentations, highlighting innovations in drug delivery, exercise interventions, artificial intelligence and computational biology, cancer stem cell plasticity, and translational research approaches. The meeting emphasised mechanistically informed strategies, multi-modal therapies, and the integration of patient-relevant models to improve therapeutic outcomes. The sessions collectively underscored the importance of combining biological, chemical, and physical approaches, as well as emerging tools in precision oncology, to address therapeutic resistance and enhance patient care.
Open AccessIntegrating Lifestyle, Mechanistic Therapeutics, and Computational Approaches in Cancer: Highlights from the Irish Association for Cancer Research Annual Conference 2025
The Irish Association for Cancer Research (IACR) Annual Conference 2025, held in Belfast, showcased cutting-edge developments across the cancer research landscape. This report summarizes key presentations, highlighting innovations in drug delivery, exercise interventions, artificial intelligence and computational biology, cancer stem cell plasticity, and translational research approaches. The meeting emphasised mechanistically informed strategies, multi-modal therapies, and the integration of patient-relevant models to improve therapeutic outcomes. The sessions collectively underscored the importance of combining biological, chemical, and physical approaches, as well as emerging tools in precision oncology, to address therapeutic resistance and enhance patient care.
- Open Access
- 8 June 2026
- Published by Elsevier in SSRN Electronic Journal
Cytoplasmic Androgen Receptor Reprograms Stress Granule–Mediated mRNA Sequestration in Breast Cancer
Endocrine resistance is a major barrier in estrogen receptor–positive (ER+) breast cancer, yet post‑transcriptional contributions remain unclear. Stress granules (SGs) are dynamic ribonucleoprotein assemblies that regulate mRNA fate during stress and support cancer cell survival, but their role in endocrine resistance is not well defined. Building on evidence that cytoplasmic androgen receptor (AR) interacts with the SG protein G3BP1, we hypothesized that AR–SG coupling rewires translational control to promote survival. We identify cytoplasmic AR as a regulator of SG function that drives adaptive post‑transcriptional reprogramming in aromatase inhibitor (AI)–resistant models. Using 2D/3D systems, imaging, RNA immunoprecipitation sequencing, we show that androgens induce AR–G3BP1 SG complexes that selectively sequester stress‑response transcripts, altering translation. In resistant cells, AR‑dependent SG remodeling reduced translation of key targets including PARP1 and EGR1. Disrupting SG assembly with epigallocatechin gallate selectively impaired resistant cell viability, reversible with androgen deprivation. Analysis of primary tumors (n=57) showed enrichment of cytoplasmic AR–SG complexes in aggressive subtypes. These findings define an AR–G3BP1 condensate axis linking steroid signaling to RNA regulation and highlight SG dynamics as a therapeutic vulnerability.
- 8 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCytoplasmic Androgen Receptor Reprograms Stress Granule–Mediated mRNA Sequestration in Breast Cancer
Endocrine resistance is a major barrier in estrogen receptor–positive (ER+) breast cancer, yet post‑transcriptional contributions remain unclear. Stress granules (SGs) are dynamic ribonucleoprotein assemblies that regulate mRNA fate during stress and support cancer cell survival, but their role in endocrine resistance is not well defined. Building on evidence that cytoplasmic androgen receptor (AR) interacts with the SG protein G3BP1, we hypothesized that AR–SG coupling rewires translational control to promote survival. We identify cytoplasmic AR as a regulator of SG function that drives adaptive post‑transcriptional reprogramming in aromatase inhibitor (AI)–resistant models. Using 2D/3D systems, imaging, RNA immunoprecipitation sequencing, we show that androgens induce AR–G3BP1 SG complexes that selectively sequester stress‑response transcripts, altering translation. In resistant cells, AR‑dependent SG remodeling reduced translation of key targets including PARP1 and EGR1. Disrupting SG assembly with epigallocatechin gallate selectively impaired resistant cell viability, reversible with androgen deprivation. Analysis of primary tumors (n=57) showed enrichment of cytoplasmic AR–SG complexes in aggressive subtypes. These findings define an AR–G3BP1 condensate axis linking steroid signaling to RNA regulation and highlight SG dynamics as a therapeutic vulnerability.
- Open Access
- 17 March 2026
- Published by Springer Nature in npj Breast Cancer
- Vol. 12 (1)
Androgen receptor localisation and protein interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer
Aromatase inhibitors (AI) are standard therapy for hormone receptor–positive breast cancer in post-menopausal women, yet recurrence remains common. Our previous work suggests that an androgen‑dominated steroid environment may drive AI resistance. Although most androgen research has focused on classical genomic pathways in reproductive tissues, interest is growing in their non‑reproductive functions. In particular, the role of cytoplasmic AR has recently gained attention, and its connection to metabolic modulation remains largely unexplored in the context of breast cancer. Cytoplasmic AR was evaluated in a breast cancer microarray (n = 875), validated in an independent cohort (n = 30), and examined in metastatic biopsies (n = 12). LC‑MS/MS identified AR‑interacting proteins in AI‑resistant cells exposed to adrenal androgens, confirmed by co‑immunoprecipitation and imaging. High cytoplasmic AR predicted poor survival in post‑menopausal patients, especially luminal B cancers (p = 0.0085). AI‑resistant models showed diffuse AR localisation throughout the cytoplasm and nucleus accompanied by increased mitochondrial mass and membrane potential, and elevated oxidative phosphorylation and glycolysis. Label‑free mass spectrometry identified G3BP1, SLIRP and IGFBP5 as AR interactors linked to stress response, metabolic adaptation and ERα repression. The findings of this study highlight the prognostic potential of cytoplasmic AR immunoreactivity in specific breast cancer subtypes and uncover novel cytoplasmic AR protein interactions that may mediate metabolic adaptations during the development of endocrine-resistance.
- 17 March 2026
- Published by Springer Nature in npj Breast Cancer
- Vol. 12 (1)
Open AccessAndrogen receptor localisation and protein interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer
Aromatase inhibitors (AI) are standard therapy for hormone receptor–positive breast cancer in post-menopausal women, yet recurrence remains common. Our previous work suggests that an androgen‑dominated steroid environment may drive AI resistance. Although most androgen research has focused on classical genomic pathways in reproductive tissues, interest is growing in their non‑reproductive functions. In particular, the role of cytoplasmic AR has recently gained attention, and its connection to metabolic modulation remains largely unexplored in the context of breast cancer. Cytoplasmic AR was evaluated in a breast cancer microarray (n = 875), validated in an independent cohort (n = 30), and examined in metastatic biopsies (n = 12). LC‑MS/MS identified AR‑interacting proteins in AI‑resistant cells exposed to adrenal androgens, confirmed by co‑immunoprecipitation and imaging. High cytoplasmic AR predicted poor survival in post‑menopausal patients, especially luminal B cancers (p = 0.0085). AI‑resistant models showed diffuse AR localisation throughout the cytoplasm and nucleus accompanied by increased mitochondrial mass and membrane potential, and elevated oxidative phosphorylation and glycolysis. Label‑free mass spectrometry identified G3BP1, SLIRP and IGFBP5 as AR interactors linked to stress response, metabolic adaptation and ERα repression. The findings of this study highlight the prognostic potential of cytoplasmic AR immunoreactivity in specific breast cancer subtypes and uncover novel cytoplasmic AR protein interactions that may mediate metabolic adaptations during the development of endocrine-resistance.
- Open Access
Androgen receptor interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer
Purpose: Aromatase Inhibitors (AI) are standard therapy for hormone receptor positive breast cancers in post-menopausal patients. Disease recurrence is common and previous studies suggest that the altered steroid environment may be a driver of resistance. Using label-free mass-spectrometry we explored the unique androgen receptor (AR) interactome that supervenes in AI resistant breast cancer and the associated hyperandrogenic environment. Experimental Design: AR expression was evaluated in a primary breast cancer tissue-microarray (n=875) with nuclear and cytoplasmic localization quantified. Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) analysis was utilized to identify proteins interacting with the AR in models of AI-resistance. Validation was carried out by co-immunoprecipitation and co-localisation studies. Live-cell imaging, Seahorse MitoStress Assays and flow cytometry were used to quantify changes in mitochondria and cell metabolism arising in models of AI-resistance. Results: Utilising digital pathology we detected that abundant cytoplasmic AR protein was associated with poor survival only in the post-menopausal cohort, and most significantly, in the therapy-refractory Luminal B subtype (p=0.0085). Models of AI-resistance and androgen excess highlight diffuse AR localisation throughout the cytoplasm and nucleus accompanied by increased mitochondrial mass and membrane potential, and increased oxidative phosphorylation and glycolysis. Exploration of the AR protein interactome identified G3BP1, SLIRP, and IGFBP5 as AR protein partners which are associated with stress, adaptive metabolic response and estrogen receptor repression. Conclusions: The findings of this study highlight the prognostic potential of cytoplasmic AR immunoreactivity in specific breast cancer subtypes and uncover novel extra-nuclear AR protein interactions that may mediate metabolic adaptations during the development of endocrine-resistance.
Open AccessAndrogen receptor interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer
Purpose: Aromatase Inhibitors (AI) are standard therapy for hormone receptor positive breast cancers in post-menopausal patients. Disease recurrence is common and previous studies suggest that the altered steroid environment may be a driver of resistance. Using label-free mass-spectrometry we explored the unique androgen receptor (AR) interactome that supervenes in AI resistant breast cancer and the associated hyperandrogenic environment. Experimental Design: AR expression was evaluated in a primary breast cancer tissue-microarray (n=875) with nuclear and cytoplasmic localization quantified. Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) analysis was utilized to identify proteins interacting with the AR in models of AI-resistance. Validation was carried out by co-immunoprecipitation and co-localisation studies. Live-cell imaging, Seahorse MitoStress Assays and flow cytometry were used to quantify changes in mitochondria and cell metabolism arising in models of AI-resistance. Results: Utilising digital pathology we detected that abundant cytoplasmic AR protein was associated with poor survival only in the post-menopausal cohort, and most significantly, in the therapy-refractory Luminal B subtype (p=0.0085). Models of AI-resistance and androgen excess highlight diffuse AR localisation throughout the cytoplasm and nucleus accompanied by increased mitochondrial mass and membrane potential, and increased oxidative phosphorylation and glycolysis. Exploration of the AR protein interactome identified G3BP1, SLIRP, and IGFBP5 as AR protein partners which are associated with stress, adaptive metabolic response and estrogen receptor repression. Conclusions: The findings of this study highlight the prognostic potential of cytoplasmic AR immunoreactivity in specific breast cancer subtypes and uncover novel extra-nuclear AR protein interactions that may mediate metabolic adaptations during the development of endocrine-resistance.
- Open Access
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Steroid profiles of breast cancer patient serum (recurrent versus non-recurrent).
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Steroid profiles of breast cancer patient serum (recurrent versus non-recurrent).
- Open Access
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 4 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Androstenedione driven gene changes post AI therapy (+ months)
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 4 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Androstenedione driven gene changes post AI therapy (+ months)
- Open Access
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Univariate analysis of AR by subtypes
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Univariate analysis of AR by subtypes
- Open Access
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 3 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
TMA images showing AR expression level by IHC in samples used in trasnscriptomic analysis
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 3 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
TMA images showing AR expression level by IHC in samples used in trasnscriptomic analysis
- Open Access
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 1 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
KM survival data based on therapy
- 7 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 1 from Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
KM survival data based on therapy